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The study aimed to identify early echocardiographic and circulating biomarkers of heart failure (HF) in
hypertensive patients with normal resting echocardiography. Echocardiography at rest and during exercise,
and selected biomarkers were assessed in control group, dyspnea group, andHF group. On exercise dyspnea
patients had lower early diastolic (E’) and systolic (S’) mitral annular velocity (12.86 1.0 vs 14.96 3.0 cm/sec
and 9.36 2.0 vs 10.96 2.0 cm/sec, respectively), and higher E/E’ ratio compared to control group (6.76 1.0
vs 5.9 6 1.0) (p , 0.05 for all comparisons). The level of N-terminal propeptide of procollagen type III
(PIIINP) was significantly higher in dyspnea group than in controls (p 5 0.01). Control and dyspnea
patients had lower levels of cardiotrophin-1, cystatin C, syndecan-4, and N terminal–probrain natriuretic
peptide than HF patients (all p# 0.01). In multivariate analysis PIIINP (unadjusted odds ratio [OR]5 8.2,
95% confidence interval [Cl] 1.7–40.6; p5 0.001; adjusted OR5 8.7; 95%CI: 1.5–48.3; p5 0.001) and E/E’
ratio on exercise (unadjusted OR5 1.8, 95%CI: 0.8–4.0; p5 0.033; adjusted OR5 2.0; 95%CI: 0.8–4.8; p5
0.012) were the only factors significantly associated with the presence of dyspnea. PIIINP is the first early
biomarker for the HF development in patients with HA and normal resting echocardiography. Exertional
echocardiography may indicate patients with incipient HF with preserved ejection fraction.
C
ardiovascular disease (CVD) is the leading cause of death. Importantly, it remains the foremost cause of
preventable death globally1. The reason for the enormous burden of hypertension has been reported in
numerous studies, showing that hypertensive disease is strongly associatedwith overall CV risk1/Increased
blood pressure (BP) contributes indeed to both CV and cerebrovascular endpoints, including heart failure (HF),
myocardial infarction (MI), and stroke1. As reported in 2013 statistics of the American Heart Association, 33.0%
of US adults $ 20 years of age have hypertension1.
HF prevalence continues to rise in developed countries, particularly in the elderly2. HF is a progressive disease
with a preclinical phase (stage B HF) characterized by the presence of structural and/or functional cardiac
abnormalities that precede the development of the overt disease3. Hypertension is a major cause of HF through
induction of left ventricular hypertrophy (LVH) and coronary atherosclerosis. LVH is due not only to cardiac
myocyte hypertrophy but also to increase in the extracellular matrix and collagen structure3,4. In hypertensive
patients, LVH is often associated with exertional dyspnea. However, hypertensive patients independent of
presence of LVH on resting echocardiogram, may have abnormal left ventricular function that may be diagnosed
only during exercise and explaining exertional dyspnea4,5. Hypertension is a main cause of HF with preserved
ejection fraction (HFpEF), although this represents a heterogeneous disease6. Major pathophysiological factors
implicated in HFpEF are impaired relaxation, increased LV stiffness and reduced compliance, atrial dysfunction,
chronotropic incompetence, pre- and post-capillary pulmonary hypertension, and vascular stiffening6,7. Low-
grade inflammation and extracellular matrix accumulation and fibrosis are often described, andmay significantly
contribute to impaired LV filling, a hallmark of the disease6,7. Although echocardiography is the most useful non-
invasive diagnostic method for evaluating systolic and diastolic dysfunction, current state-of-the-art echocardio-
graphy has limited value for prognostication inHF8. In fact echocardiography at rest may not distinguish between
stage B HF patients and HFpEF patients9. HF results from a complex interplay between genetic, neurohormonal,
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inflammatory, and biochemical changes acting on cardiac myocytes
and the cardiac interstitium. Thus, the sequence of events that lead to
overt changes in the ventricle begins at the cellular level and assessing
these phenomena could be of greater value to improve prognostica-
tion9,10. Some important polymorphisms linked to hypertension
including calcium/calmodulin-dependent kinase IV and G-pro-
tein-coupled receptor kinases open new potential fields of trans-
lational investigation to treat patients with hypertension9,10.
Biomarkers may play an important part in this respect. They may
provide important information on the pathogenesis of HF, but may
also be a valuable clinical tool in the identification of patients at risk
for HF, in the diagnosis of HF, in risk stratification, and in the
therapy monitoring8,11,12. There are several biomarkers from differ-
ent biological pathways reflecting the multi-systemic character of
HF, which should be considered based on the analysis of the
available literature8–12: N terminal-probrain natriuretic peptide
(NT-proBNP) - biomarker of myocyte stress and gold standard for
HF; cardiotrophin-1 (CT-1) - a member of the interleukin-6 (IL-6)
family of cytokines; tumour necrosis factor-alpha (TNF-alpha) -
a proinflammatory cytokine, IL-1 receptor like protein 1 (IL1R1)
- a receptor for proinflammatory cytokine IL-1; cystatin C (CysC)
-a low-molecular weight protein from the group of cysteine protei-
nase inhibitors; transforming growth factor-beta 1 (TGF-beta 1) - a
central regulator of cardiac fibrosis; N-terminal propeptide of pro-
collagen type III (PIIINP) - one of the biomarkers of extracellular
matrix remodeling; galectin-3 - a protein involved in cell adhesion,
cell activation, chemoattraction, cell growth, cell differentiation,
fibroblast activation and apoptosis; syndecan-4 - a biomarker of left
ventricular remodeling; neutrophil gelatinase-associated lipocalin
(lipocalin-2/NGAL) - a glycoprotein involved in cell survival, inflam-
mation and matrix degradation8–12.
The main aim of the study was to identify echocardiographic
markers during exercise and circulating biomarkers characterizing
hypertensive patients with exertional dyspnea. This study reviews the
hypothesis that circulating biomarkers and exertional echocardio-
graphy allow for early identification of hypertensive patients at risk
of HF. The study was also designed to try establish the panel of
diagnostic tests in patients with hypertension, which will allow for
early detection of abnormalities and to clarify the etiology of exer-
tional dyspnea in patients with hypertension and normal resting
echocardiography.
Methods
Study population. 120 patients with stage I or II essential hypertension13 were
included consecutively in the study between October 2012 to February 2014. The
exclusion criteria were as follows: coronary artery disease (CAD) or a history of CAD,
unstable hypertension, New York Heart Association (NYHA) class IV HF,
percutaneous or surgical revascularization, evidence of pulmonary hypertension on
echocardiography, obstructive or restrictive pulmonary disease (groups control and
dyspnea, congenital or valvular heart disease, the presence of arrhythmia (including
atrial fibrillation [AF]), electrical pacemaker or implantable cardiac defibrillators,
hyperthyroidism and hypothyroidism, pregnancy and lactating, hemodynamically
significant acquired heart defects, cardiomyopathies (in control and dyspnea groups),
glomerular filtration rate (GFR) , 60 ml/min/1.73 m2 (in control and dyspnea
groups), chronic liver insufficiency, cancer, significant anemia, abuse of alcohol or
drugs, chronic inflammatory and other diseases, or lack of informed consent to
participate in the study.
Dyspnea was graded by the NYHA functional classification14. Angina pectoris was
graded by the Canadian Cardiovascular Society (CCS) scale15. The venous blood
samples were drawn fasting in the morning and the obtained serum was frozen at the
temperature of 70uC. Estimated GFR was calculated using theModification of Diet in
Renal Disease (MDRD) formula16. Systolic and diastolic arterial pressures were
measured using a sphygmomanometer and stethoscope at rest and after exercise.
Approval from the Bioethics Commission of the Medical University of Lodz (No.
RNN/749/13/KB) was obtained. All the methods were performed in accordance with
approved guidelines. Written informed consent was obtained from all the patients.
Biomarker tests. The concentrations of NT-proBNP, CT-1, CysC, TNF-alpha,
PIIINP, syndecan-4, IL1R1, TGF-beta 1 and lipocalin-2/NGAL were determined
using the EMaxH Endpoint ELISA Microplate Reader analyzer (Molecular Devices;
Sunnyvale, California, USA). TNF-alpha was analyzed with the enzyme-linked
immunosorbent assay (ELISA) (Diaclone/Gen-Probe, USA), with 2 polyclonal
antibodies directed against TNF-alpha. Determination of NT-proBNP and CT-1 was
performed with reagents of USCN Life Science Inc./Cloud-Clone Corp (Wuhan,
China), using a sandwich ELISA assay according to the manufacturer’s protocol.
Measurement of CysC was performed using a sandwich enzyme immunoassay
(BioVendor, Brno, Czech Republic) developed for the quantitative measurement of
this marker in human serum. Analysis of the concentration of PIIINP, syndecan-4
and IL1RL1 was performed with a USCN Life Science Inc./Cloud-Clone Corp
(Wuhan, China) kit, using a sandwich ELISA assay according to the manufacturer’s
protocol. Measurement of TGF-beta 1 was performed using a sandwich enzyme
immunoassay (Gen-Probe Diaclone SAS, Besançon, France) designed for the
quantitative detection of TGF-beta 1 levels in cell culture supernatants, human serum,
plasma or other body fluids. Determination of lipocalin-2/NGAL was conducted
using the BioVendor Human Lipocalin-2/NGAL ELISA sandwich enzyme
immunoassay. Analysis of the concentration of galectin-3 was performed with a
USCN Life Science Inc./Cloud-Clone Corp (Wuhan, China) kit, using a sandwich
ELISA assay.
Echocardiography. All patients were examined following a standardized protocol
using an ALOKA Alpha 10 Premier (Tokyo, Japan) with a 3–11 MHz probe.
Quantitative echocardiography was used following current guidelines17. Left
ventricular volumes and ejection fraction (EF) was determined by biplane Simpson’s
method. Left ventricular (LV) mass was calculated using the Devereux formula. The
early (E) and atrial filling (A) peak velocities, E/A ratio, deceleration time of early
filling and isovolumic relaxation time were measured from transmitral flow. Peak
systolic (S’), early diastolic (E’) and late diastolic (A’) mitral annular myocardial
velocity of the left ventricle septal and lateral walls was recorded from the apical 4-
chamber view with pulsed-wave tissue Doppler and results were averaged. The E/E’
was calculated as an index of LV filling pressure. All measurements were made off-
line on three consecutive beats and averaged values are reported.
Exercise testing. Symptom-limited (fatigue, dyspnea or stenocardia) exercise testing
was done in groups control and dyspnea on a bicycle ergometer to a HR of less than
100 bpm.
Statistical analysis. The STATISTICA 10 software package (StatSoft, Poland) was
used for analysis. All values presented are the mean 6 standard deviation (SD) for
continuous variables and number and percentages for categorical variables. To
compare two groups, Student’s t-test for continuous variables with normal
distribution and Mann-Whitney U test for non-normally distributed variables was
used. For comparison of three groups analysis of variance (ANOVA) with post-hoc
Tukey’s test for unequal sample sizes or Kruskal-Wallis ANOVA was used as
appropriate. Correlations between variables were tested with Spearman’s rank
correlation coefficient. Bootstrapped logistic regression was used to identify factors
significantly associated with the presence of dyspnea. All the echocardiographic
images were analysed by the single investigator. The intraobserver variability was
performed in 10 randomly selected patients at rest and during exercise and reported
as interclass correlation coefficient (ICC) with 95% CI. A value of p , 0.05 was
considered significant.
Results
General characteristics of patients. There were 150 patients
potentially eligible for the study, 120 of patients were examined
for eligibility, 21 patients were excluded (2 had CAD, 4 had AF
and 15 did not have adequate exercise images for analysis). The
remaining 99 hypertensive patients were grouped into 3 groups: 22
asymptomatic hypertensive patients (control group), 27 patients
with exertional dyspnea (dyspnea group) and 50 hypertensive
patients with overt HF. HF patients were defined using combined
criteria: clinical symptoms and LVEF,50%. Patients in control and
dyspnea groups had normal resting echocardiography. Because
patients with hypertension are more likely to develop coronary
artery disease18, dyspnea group included only patients with negative
results of treadmill exercise testing and who had undergone com-
puted tomography coronary angiography without any identified
changes in the epicardial coronary arteries and Agatston score 0.
The patients’ characteristics are presented inTable 1. Compared to
asymptomatic patients, hypertensive patients with dyspnea more
frequently reported stenocardia. Compared to HF patients, hyper-
tensive patients with dyspnea had significantly higher BP, MDRD
GFR, and calcium channel blockers and sartans were used more
frequently in this group. In successive groups there was an increase
in degree of HF according to NYHA class.
HF biomarkers in hypertensive patients. Higher concentrations of
collagen III N-terminal propeptide were observed in patients with
www.nature.com/scientificreports
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hypertension with dyspnea compared to asymptomatic patients with
hypertension (2.9 6 0.94 vs 1.27 6 1.03; p 5 0.0001) (Table 1),
concentrations of PIIINP did not differ between hypertensive
patients with dyspnea and HF patients (Figure 1). Compared to
the asymptomatic hypertensive patients, hypertensive patients with
dyspnea had similar values of other biomarkers. Compared to HF
patients, hypertensive patients with dyspnea had significantly lower
values of CT-1, syndecan, NT-proBNP, CysC, TGF beta and NGAL
(p, 0.0001; p 5 0.0015; p, 0.0001; p 5 0.0001; p, 0.0001 and p 5
0.036 respectively). The detailed data on biomarkers in investigated
groups is presented in Table 1.
Echocardiographic findings at rest.Compared to the asymptomatic
hypertensive patients, hypertensive patients with dyspnea had longer
isovolumic relaxation time (p5 0.033). Compared to dyspnea group,
patients with HF had larger dimensions (p , 0.0001), LV volumes
Table 1 | Characteristics of groups of patients without symptoms (control), with exertional dyspnea (dyspnea) and with clinical heart failure
Parameter
SD p
Control Group
N 5 22
Dyspnea Group
N 5 27
Heart Failure Group
N 5 50
Control vs
Dyspnea
Control vs
Heart Failure
Dyspnea vs
Heart Failure
Age (years) 59.5 6 13 63.5 6 9 64.5 6 11 ns ns ns
Duration of hypertension
(years)
12.4 6 7 9.3 6 6 13.9 6 6 ns ns ns
BMI kg/m2 27.0 6 5 27.6 6 4 28.6 6 4 ns ns ns
GFR MDRD (ml/min/1,73 m2) 88.4 6 8 90 6 6 67.7 6 24 ns 0.0009 0.0001
Systolic BP mmHg 136 6 7 135 6 9 122 6 15 ns 0.0001 0.0001
Diastolic BP mmHg 79 6 9 83 6 7 75 6 8 ns ns 0.001
HR 71 6 6 70 6 6 74 6 9.8 ns ns ns
Hemoglobin 14.3 6 0.9 14.4 6 1 13.8 6 1 ns ns ns
Hematocrit 41.4 6 3 41.4 6 4 42.5 6 4 ns ns ns
Nammol/l 140.9 6 4 138.8 6 3 138.4 6 3 ns ns ns
Kmmol/l 4.3 6 0.5 4.1 6 0.4 4.3 6 0.4 ns ns ns
Creatinine 0.8 6 0.24 0.9 6 0.28 1.1 6 0.29 ns ns ns
CRP mg/l 2.3 6 1 2.2 6 1.4 3.6 6 4.7 ns ns ns
TNF-alpha (pg/ml) 28.45 6 23 36.46 6 57 30.94 6 16 ns ns ns
IL1R1(ng/ml) 0.37 6 0.2 0.52 6 0.3 0.35 6 0.1 ns ns ns
TGF-beta 1(ng/ml) 11.55 6 2 9.96 6 3 5.98 6 2.5 ns ,0.0001 ,0.0001
Syndecan (ng/ml) 1.19 6 1 1.54 6 1 4.14 6 3.3 ns ,0.0001 0.0015
Galectin-3 (ng/ml) 22.27 6 6 20.45 6 4 18.59 6 11 ns ns ns
Cardiotrophin (pg/ml) 77.66 6 81 98.04 6 136 229.51 6 129 ns ,0.0001 ,0.0001
NT-proBNP (pg/ml) 146.68 6 102 152.93 6 126 1889 6 3368 ns ,0.0001 ,0.0001
Cystatin C (mg/l) 0.77 6 0.3 0.84 6 0.5 1.37 6 0.8 ns 0.0004 0.0001
Lipocalin-2 NGAL (ng/ml) 63.00 6 37 66.56 6 35 50.71 6 45 ns ns 0.0360
PIIINP (ng/ml) Median
(Q25–Q75)
1.27 6 1.03 2.9 6 0.94 2.62 6 0.97 0.0001 0.0001 ns
1.3 (0.3–2.0) 2.9 (2.2–3.6) 2.6 (1.9–3.3)
Chi-square P
Gender (male) 9(41) 13(48) 43(86) 19.7 0.0001
Smoking 2(9) 2(7) 2(4) 0.81 ns
Heart Failure acc. NYHA 73.0 0.0001
I 0 14(51) 5(10)
II 0 13(48) 21(42)
III 0 0 24(48)
IV 0 0 0
Stenocardia acc. CCS 85.5 0.0001
0 21(95) 6(22) 2(4)
I 1(5) 4(15) 34(68)
II 0 17(63) 13(26)
III 0 0 1(2)
Diabetes mellitus or
abnormal glucose level
2(9) 5(18) 8(16) 0.96 ns
Statins 69(27) 15(55) 32(64) 8.5 0.0141
Insulin 2(10) 2(7) 3(6) 0.2 ns
Diuretics 8(36) 13(48) 46(92) 30.4 0.0001
Beta -blockers 16(72) 22(81) 48(96) 8.5 0.013
Spironolactone/eplerenone 2(9) 5(18) 41(82) 50.7 0.0001
Acetylsalicylic acid 4(18) 13(49) 26(53) 8.3 0.015
ACE-inhibitors 11(50) 11(40) 43(86) 19.8 0.0001
ARBs 10(45) 12(44) 8(16) 10.0 0.006
CCB 10(45) 6(22) 4(8) 12.8 0.001
Digoxin 0 0 12(24) 18.0 0.0001
ABBREVIATIONS: BMI, body mass index; GRF MDRD, glomerular filtration rate on the basic of the study Modification of Diet in Renal Disease; BP, blood pressure; HR, heart rate; Na, sodium; K,
potassium; NYHA, New York Heart Association classification for heart failure; CCS, Canadian Cardiovascular Society; TGF-beta 1, transforming growth factor beta 1; NT-proBNP, N-terminal pro-brain
natriuretic peptide; NGAL, neutrophil gelatinase-associated lipocalin; PIIINP, collagen III N-terminal propeptide; TNF alpha, tumor necrosis factor alpha; IL1R1, interleukin 1 receptor, type I, ACE-inhibitors,
angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; CCB – calcium channel blocker.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8916 | DOI: 10.1038/srep08916 3
(p, 0.0001), lower LVEF (p, 0.0001), greater wall thickness of the
left ventricle (p, 0.02), increased LV mass and LV mass index (p 5
0.001), lower E’, S’, increased E/E’ ratio (p , 0.05) and significantly
increased left atrial (LA) diameter (p , 0.0001) (Table 2).
Findings during exercise echocardiography. The increase in E9
with exercise was significantly smaller in patients with symptoms
compared with control subjects with D E’ (p 5 0.004) and the
increase of E/E’ ratio (p 5 0.017; p 5 0.020; and p 5 0.034,
respectively). On exercise systolic and early diastolic velocities of
mitral annulus were increased both in control and dyspnea group
and the values were significantly higher in control group than in
dyspnea group (p 5 0.02; p 5 0.01, respectively) (Table 3). There
was a significant decrease in the E/E’ after exercise only in control
group (p 5 0.02). Figure 2 presents values of E/E’ in both groups
before and during exercise. On exercise we also observed a late
diastolic mitral annular velocity (A’) increase only in control group
with a significant difference in DA’ between these two groups (p 5
0.04). The detailed echocardiographic data is presented in Table 3.
Reproducibility.All the echocardiographic images were analysed by
the same investigator. The intraobserver variability by ICC at rest
varied from 0.87 to 0.98 and on exercise from 0.75 to 0.97.
Multivariate logistic regression analysis. Variables significant in
univariate comparisons (p , 0.10) were included into multivariate
logistic regression model with bootstrap correction to identify the set
of the statistically significant risk factors for dyspnea. Sex and age
were added to the model as confounders.
In multivariate analysis PIIINP (unadjusted odds ratio [OR] 5
8.2, 95% confidence interval [Cl] 1.7–40.6; p 5 0.001; adjusted
OR 5 8.7; 95%CI: 1.5–48.3; p 5 0.001.) and E/E’ ratio on exercise
(unadjustedOR5 1.8, 95%CI: 0.8–4.0; p5 0.033; adjustedOR5 2.0;
95%CI: 0.8–4.8; p 5 0.012) were the only factors significantly assoc-
iated with the presence of dyspnea (Table 4).
Discussion
Significance of the study. Currently, patients with hypertension are
defined as HF group A3 despite the absence of signs and symptoms,
due to the high risk of developing of the disease. Patients with
hypertension, even well controlled, without LVH and with normal
resting echocardiography, may have symptoms of HF only during
exercise, usually in the form of exertional dyspnea3. The origin of the
symptoms of myocardial dysfunction in these groups of patients is
still unclear. One of the hypotheses involves myocardial stiffness and
impaired relaxation3.
Various markers of LV systolic and diastolic function derived
from Doppler echocardiography have been used to predict LV func-
tional capacity19,20. However, mitral inflow is dependent on LV
relaxation and LA pressure, thus the confounding effects of changes
in loading conditions can significantly affect the measurements
determined by Doppler recordings of LV filling velocities19,20.
Tissue Doppler imaging (TDI) records systolic and diastolic velocit-
ies within the myocardium, and has been shown to provide accurate
quantification of regional and global LV function19,20.
Studies have shown that HFpEF is characterized by an increase in
cardiomyocyte stiffness, but also by production and deposition of
extracellular matrix21,22. Cardiac fibrosis is difficult to quantify and in
Figure 1 | Concentrations of PIIINP in the investigated groups.
ABBREVIATIONS: PIIINP – collagen III N-terminal propeptide.
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this regard more sensitive biomarkers that are easy to measure are
very important21,22. Therefore we added TDI derived parameters
to other standard Doppler echocardiographic measurements and
evaluated the levels of selected biochemical biomarkers to find
potential predictors of impaired exercise capacity in patients with
hypertension.
Brief description of results. In our study significantly higher con-
centrations of PIIINP were observed in patients with hypertension
with exertional symptoms and in patients with advanced HF
compared to the control group, which might suggest that PIIINP
may be the first, early biomarker of HF in patients with
hypertension. It was the only biomarker that essentially differed
between control, dyspnea and HF group. Other investigated
biomarkers showed significant differences only between hyper-
tensive patients with normal resting echocardiography (control
and dyspnea groups) and patients with advanced HF. Hypertensive
patients with preserved EF (control and dyspnea groups) had
comparable echocardiographic findings at rest except isovolumic
relaxation time (IVRT), which was significantly longer in the
dyspnea group (p 5 0.03). In exertional echocardiography the
patients in dyspnea group had lower peak early diastolic mitral
annular velocity (E’) and peak systolic mitral annular velocity (S’)
according to TDI and E/E’ ratio was significant higher in the
Table 2 | Resting echocardiography parameters in each group
Parameter
Mean 6 standard deviation (SD) p
Control Group
(n522)
Dyspnea Group
(n527)
HF Group
(n550)
Control vs
Dyspnea
Control vs
Heart Failure
Dyspnea vs
Heart Failure
LVEDD (mm) 50.8 6 6 49.0 6 5 63.2 6 9.5 ns ,0.0001 ,0.0001
LVESD (mm) 30.5 6 5 32.5 6 6 48.1 6 10 ns ,0.0001 ,0.0001
LVEF (%) 62.5 6 4 59.5 6 3 36.7 6 10 ns ,0.0001 ,0.0001
LA (mm) 35.9 6 5 37.1 6 4 45.1 6 7.7 ns ,0.0001 ,0.0001
Dilated LA (%) 36 26 74 ns ,0.001 ,0.001
peak E cm/s 70.1 6 11 71.3 6 18 62.9 6 23 ns ns ns
peak A cm/s 65.3 6 23 70.3 6 16 87.4 6 13 ns 0.019 ns
E/A ratio 1.1 6 0.4 1.0 6 0.3 0.6 6 0.2 ns 0.012 ns
DT (ms) 246.2 6 58 267.7 6 72 343.1 6 106 ns ns Ns
LV mass (g) 193.0 6 51 194 6 61 460 6 244 ns 0.001 0.001
LVMI 104.2 6 31 103.7 6 24 240 6 132 ns 0.001 0.001
IVSD (mm) 9.5 6 1 9.3 6 1 11.7 6 2.3 ns 0.003 ,0.0001
PWD (mm) 9.1 6 1 9.3 6 1 11.3 6 2.8 ns 0.019 0.019
RVdD (mm) 27.9 6 3 26.8 6 3 28.8 6 4.8 ns ns ns
LVEDV (ml) 85.8 6 25 80.6 6 21 213.5 6 60 ns ,0.0001 ,0.0001
LVESV (ml) 29.8 6 7 28.2 6 8 135.5 6 50 ns ,0.0001 ,0.0001
TAPSE (mm) 25.9 6 3 24.5 6 3 21.6 6 3.6 ns 0.004 ns
IVRT (ms) Rest 89.4 6 26 104.8 6 19 105.1 6 15 0.03 0.03 ns
E’ Rest (cm/s) 10.5 6 2 10.7 6 2 6.4 6 3 ns 0.01 0.01
A’ Rest (cm/s) 10.8 6 3 11.3 6 3 11.8 6 2 ns ns ns
E/E’ ratio Rest 7.0 6 2 7.0 6 1 10.6 6 5 ns 0.02 0.02
S’ rest (cm/s) 9.0 6 2 9.0 6 2 6.0 6 3 ns 0.02 0.02
ABBREVIATIONS: LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; LA, left atrial diameter; E, early mitral diastolic inflow
velocity; A, late mitral diastolic inflow velocity; E/A, ratio of early to late mitral inflow velocities; DT, deceleration time of peak early mitral filling velocity; LVMI, left ventricular mass index; IVSD, diastolic
interventricular septal thickness; PWD, diastolic posterior wall thickness; RVDD, right ventricular diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVSV, left ventricular systolic volume; TAPSE,
tricuspid annular plane systolic excursion; IVRT, isovolumic relaxation time; E’, early diastolic annular velocity; A’, late diastolic annular velocity; E/E’, ratio of early mitral diastolic inflow velocity to early
diastolic mitral annular velocity; S’, systolic mitral annular velocity
Table 3 | Evaluation of selected parameters in control group and in dyspnea group during exercise
Parameter
Mean 6 standard deviation (SD) p
Control Group (n522) Dyspnea Group (n527) Control vs Dyspnea
Efficiency in MET 8.2 6 1 7.1 6 1 ns
Systolic BP mmHg Ex 160 6 18 165 6 19 ns
Diastolic BP mmHg Ex 85 6 10 87 6 12 ns
HR Ex 91 6 5 93 6 6 ns
peak E Ex (cm/s) 85.5 6 21 88.7 6 19 ns
peak A Ex (cm/s) 74.9 6 25 73.5 6 18 ns
E/A ratio Ex 1.2 6 0.5 1.2 6 0.4 ns
DT Ex (ms) 239.3 6 78 260 6 70 ns
E’ Ex (cm/s) 14.9 6 3 12.8 6 1 0.020
D E’ 4.4 6 3.76 2.2 6 2.41 0.004
A’ Ex (cm/s) 12.0 6 4 10.7 6 3 ns
D A’ 1.2 6 3.41 20.6 6 2.46 0.040
E/E’ ratio Ex 5.1 6 1 6.7 6 1 0.034
S’ Ex (cm/s) 10.9 6 2 9.3 6 2 0.017
ABBREVIATIONS:MET, metabolic equivalent defined as the amount of oxygen consumed while sitting at rest and is equal to 3.5 ml O2 per kg body weight x min; Ex, on exercise; BP, blood pressure; HR,
heart rate E’, early diastolic annular velocity; D E’5 E’ Ex - E’ rest; A’, late diastolic annular velocity; D A’5 A’ Ex - A’ rest; E/E’, ratio of early mitral diastolic inflow velocity to early diastolic mitral annular
velocity; S’, systolic mitral annular velocity; Ex, on exercise.
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symptomatic group as compared to controls. On exercise we also
observed the increase of a late diastolic mitral annular velocity (A’) in
patients without symptoms. Based on multivariate regression
analysis, the only independent factors of dyspnea were PIIINP and
E/E’ ratio on exercise.
PIIINP as an early biomarker of HF in hypertensive patients. The
circulating markers of collagen metabolism such as PIIINP and
C-terminal telopeptide of collagen I (CITP) are increased in
HFpEF patients while markers of extracellular matrix turnover and
matrix degradation such as matrix metalloproteinase 2 (MMP-2)
and MMP-9 are reduced23. In contrast to HF with reduced EF
myocardial stiffness may even be more important than extra-
cellular fibrosis as a mechanism for diastolic stiffness in HFpEF. It
has been observed that HFpEF patients with only mild elevations of
collagen volume fraction may have highly elevated LV end-diastolic
pressures23.
PIIINP and collagen I N-terminal propeptide [PINP] must
undergo a series of sequential postsynthetic processing steps in order
to become amature structural collagen fibril23,24. One of these steps is
cleavage of PINP and PIIINP. Both the propeptides and telopeptides
are of small molecular weight and thereby move from the interstitial
space into the vascular compartment, which in turn allows for quan-
tification in a systemic blood sample. In the study of Martos et al.24
PIIINP was increased in patients with LVH and HF24. Cortes et al.25
reported that serum PINP and PIIINP were increased in LVH com-
pared to non-hypertrophy (p 5 0.01 and p 5 0.005, respectively).
Moreover, serum PIIINP was associated with sFas (r 5 0.386,
Figure 2 | Values of E/E’ in both groups (Control and Dyspnea) before and during exercise.
Table 4 | Bootstrapped logistic regression results
Parameter
unadjusted adjusted for sex and age
OR 95%CI for OR p - value OR 95%CI for OR p - value
IVRT (ms) Rest 1,039 0,970 1,112 0,149 1,047 0,965 1,136 0,066
E’ Ex (cm/s) 1,103 0,578 2,105 0,403 1,256 0,552 2,859 0,141
E/E’ ratio Ex 1,803 0,814 3,994 0,033 2,016 0,844 4,816 0,012
S’ Ex (cm/s) 0,901 0,470 1,725 0,394 0,773 0,365 1,638 0,106
D E’ 0,920 0,546 1,551 0,394 0,856 0,450 1,628 0,176
D A’ 0,879 0,487 1,585 0,379 0,862 0,454 1,638 0,161
PIIINP 8,203 1,657 40,618 0,001 8,653 1,549 48,319 0,001
Model
description
Model is statistically significant: x2 5 32.72; df 5 7; p,0.001;
Nagelkerke’s R2 5 0.72; Hosmer – Lemeshaw test: x2 5 5.57;
df 5 8; p 5 0.696
Model is statistically significant: x2 5 33.41; df 5 9; p , 0.001;
Nagelkerke’s R2 5 0.73; Hosmer – Lemeshaw test: x2 5 8.11;
df 5 8; p 5 0.423
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p , 0.0001) and sTNFR1 (r 5 0.298, p , 0.001)25. Similar results
were obtained by Agriniera et al., where the authors showed that
PIIINP level was higher in the presence of LVH than without LVH
(3.26 1.0 vs. 2.66 0.8 ng/ml, p5 0.001)26. In other studies increased
PIIINP serum level was found to be associated with LV diastolic
dysfunction, LVH and NYHA functional class in hypertensive
patients27,28. In the study of Lopez et al., plasma CT-1 and NT-
proBNP and selected serum biomarkers of myocardial fibrosis were
significantly increased in hypertensive patients with HF29. Barasch
et al.30 performed a nested case-control study within the
Cardiovascular Health Study and assessed the selected biomarkers
at 5- or 9-year follow-up in the group of 880 subjects. In the total
study population, elevated PIIINP was associated with incident
HFpEF during follow-up (OR per tertile 2.2, 95% CI 1.7–2.8)30. In
community-based studies, it has been reported that PIIINP levels
increased with age and BMI. There were no difference in our study
according BMI and age between analysed groups31.
All these studies are in accordance with our results and suggest
that PIIINP as a useful marker of HF. Our study also revealed that
PIIINP is the first early biomarker of the beginning of HFpEF in
patients with hypertension and normal resting echocardiography.
Echocardiographic findings. The genesis of symptoms in patients
with HFpEF is unclear. Most investigations of HFpEF have focused
on cardiac function at rest although most of these patients are
breathless only on exercise30. The abnormalities of ventricular
function in HFpEF may not be apparent at rest but are more
obvious on exercise. With the increase in filling pressure early
mitral diastolic inflow velocity (E wave) increases with reduced
early diastolic annular velocity (wave E’). The ratio of early mitral
diastolic inflow velocity to early diastolic mitral annular velocity (E/E’)
correlates with the wedge pressure in the pulmonary artery30. The
TDI of early mitral annulus velocity has been reported to be a
relatively preload-independent index of LV relaxation, and the
ratio of peak early diastolic mitral inflow velocity to myocardial
velocity can be used to estimate LV filling pressure32. The
longitudinal expansion of the LV is reduced and delayed by slower
relaxation and not substantially influenced by LA pressure in the
presence of diastolic dysfunction. Thus, in contrast to E, E’ provides
a consistent measurement of diastolic dysfunction despite increases
in LA pressure. The peak rate of LV diastolic filling E is decreased
with mild diastolic dysfunction but progressively increased in
response to elevation in LA pressure. However, the peak E’ wave
progressively declines with HF worsening, despite increases in LA
pressure and LA to LV pressure gradient32. Thus E’ (but not E)
accurately reflects the progressive slowing of LV relaxation as HF
develops32. In the study of Ha et al.33, the increase in E9 with
exercise was significantly smaller in patients with hypertrophic
cardiomyopathy (p 5 0.0002). Kitzman et al.34 observed an
increase in LV filling pressure with exercise in patients with HF
and preserved systolic function. Similar changes have been
reported in normotensive patients with normal LVEF without
inducible myocardial ischemia and exaggerated systolic BP
response to exercise35. However, these studies did not assess the
effect of stress on the diastolic indices specifically in patients with
HFpEF. In a study by Chattopadhyay et al.36, 41 patients with
hypertension and HF symptoms only on exercise and 29 controls
underwent dobutamine stress echocardiography with color TDI. At
rest, early diastole annular tissue velocity (E’) in the group with
exertional dyspnea was similar to controls. The E’ decreased and
the E/E’ ratio increased with stress in the HFpEF but not in
controls. The 6-minute walk distance was shorter and negatively
correlated to the E/E’ ratio at rest and stress in the HFpEF
group36. The goal of the study by Terzi et al.37 was to examine
whether TDI-derived parameters add incremental value to other
standard Doppler echocardiographic measurements in predicting
exercise capacity. The study enrolled 59 consecutive patients with
stable congestive HF. Systolic and early diastolic velocities of mitral
annulus were decreased and the E/E’ ratio was increased in the
restrictive group as compared to controls, but there was no
significant difference in late diastolic velocity and E’/A’ ratio
between the restrictive group and controls37. Interestingly, the
patients with the nonrestrictive pattern and E/E’ ratio .7.5 had a
reduced exercise capacity, as did the group with restrictive LV filling
patterns. Univariate analysis demonstrated that the peak S’ (r 5 0.30,
p 5 0.03), peak E’ (r 5 0.38, p 5 0.004) and peak A’ (r 5 0.35, p 5
0.009) correlated significantly with maximum exercise capacity37.
According to multivariate analysis, the index of the E/E9 ratio
derived from dividing peak early diastolic mitral inflow velocity by
the mitral annular velocity was found to be the most powerful
predictor of peak oxygen uptake and the E/E’ ratio .7.5 enables
the functional limitation to be predicted regardless of the mitral
flow profile37. The causal relation between exercise intolerance and
induced diastolic impairment has also been demonstrated in patients
with exercise intolerance and normal LV systolic function38. Tan
et al. assessed patients with symptomatic HF and normal
echocardiographic image and the control group at rest and during
submaximal exercise standard tissue Doppler and speckle tracking
echocardiography39. At rest, systolic longitudinal and radial strain,
systolic mitral annular velocities, and apical rotation were lower in
symptomatic patients, and failed to rise normally on exercise. E9 and
E/E9 are influenced by age in healthy subjects. Age-related increases
in E/E9 do not seem to be a consequence of higher LV diastolic
pressures since left atrial pressure does not significantly rise in
healthy elderly subjects. The high values for E/E9 are common in
this setting. There were no significant age differences between our
groups20.
We showed that in exertional echocardiography the patients from
the dyspnea group had lower peak early diastolic mitral annular
velocity (E’), and E/E’ ratio was increased as compared to controls.
Our observations are consistent with other presented findings36–40.
The impaired diastolic reserve results in stress-induced increase in
the LV end-diastolic pressure, giving rise to exercise intolerance36–42.
Study limitations. There are several limitations of this study. We
assessed myocardial velocities measured by pulsed TDI and not
color-coded TDI. A limitation of this technique is the possibility to
measure the velocity of only one area at a given time. The great
advantage, however, is its availability even in the older generation
ultrasound systems, and that it does not require post-processing
work, which makes it more useful in everyday medical practice.
The diastolic blood flow and annular velocities were measured at
submaximal heart rates to avoid the problem of fusion of these
velocities at peak stress. Our echocardiographic results were not
compared with results of cardiopulmonary exercise testing. The
study involved also a relatively small number of patients and the
findings need to be confirmed in a larger population.
Conclusions. In conclusion, PIIINP is the first early biomarker for
the development of HF in patients with hypertension and normal
resting echocardiography. Patients with treated hypertension with
normal resting echocardiography can have exercise intolerance or
breathlessness and worse LV relaxation on exercise. Exertional
echocardiography using TDI may indicate patients with incipient
HFpEF and increase the diagnostic value of echocardiography in
HFpEF diagnosis.
The issue of exertional dyspnea and HF with normal ejection
fraction in patients with hypertension and normal results of resting
echocardiography is a new problem in the world. So far, there are no
treatment recommendations for this group of patients. An important
issue is the identification of patients with hypertension at risk of
developing this syndrome, the evaluation of new biochemical mar-
kers and new methods of diagnosis in this group of patients. There
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are only few studies available on this topic separately analyzing echo-
cardiography issues and usefulness of single biomarkers, thus our
project seems to be very novel and pioneering. We revealed that
circulating biomarkers of extracellular matrix remodelling and exer-
cise echocardiography could be an inexpensive and simple diagnostic
panel for the prediction of HF in patients with hypertension.
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